23 02 13 financial partner

CS MEDICA engages Kapital Partner A/S as financial advisor

CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces today that the Company has entered into an agreement with the financial advisor Kapital Partner in Denmark.  With this cooperation, the company secures valuable insights and guidance on financial decisions and strategies as well as assistance in sourcing financial partners and maximizing shareholder value.

As an efficient OTC alternative, CS MEDICA is currently first mover to bridge R&D with patent-pending products registered as medical devices with cannabidiol under the pharmaceutical regulation, Medical Device Directive (MDD), now transitioning to Medical Device Regulation (MDR).

For individuals, who seek efficient and cleaner treatments over the counter, CS MEDICA revolutionizes with innovative products and technology within the cannabis and medical industries. From discovery to manufacturing, the company commits to improving people’s lives with world-changing products that make a difference.

To secure and capitalize on CS MEDICA’s first mover status, the company has entered into an agreement with the financial advisor Kapital Partner regarding the following services:

  • Financial strategy
  • Sourcing of strategic and financial partners
  • Market Relations
  • Market compliance

Lone Henriksen, CEO CS MEDICA comments;

“We are happy to announce that we have chosen a new financial advisor who will assist us in our funding of different growth stages, and financial decisions to support us in achieving our purpose and long-term goals.”

Kapital Partner A/S
Kapital Partner is a Nordic Growth Market Mentor and Nasdaq Certified Adviser in Denmark and Sweden.  Read more about Kapital Partner at their website.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments for autoimmune and stress-related disorders under the trademark CANNASEN® or own label options.

The company is listed on Spotlight Stock Market in Denmark (symbol: “CSMED”). more information, visit cs-medica.com, and LinkedIn.